Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroMetrix

Full company profile

uuid0005b78

Namestring
NeuroMetrix
Legal namestring
NeuroMetrix, Inc.
Websiteurl
neurometrix.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

NeuroMetrix is a US-based medical device company founded in 1996 that develops and commercializes non-invasive wearable neuromodulation devices for chronic pain management and neurological disorders. The company pioneered the concept of automated nerve testing and introduced the Quell platform, billed as the first wearable nerve stimulator for managing chronic pain. Its flagship commercial product is the Quell Fibromyalgia device, an advanced wearable neuromodulator described as the first and only FDA-authorized medical device for reducing fibromyalgia symptoms.

The company's core technology is a cloud-enabled wearable neuromodulation platform that delivers non-invasive nerve stimulation to reduce chronic pain signals, paired with proprietary consumable electrode pads required for ongoing device use. NeuroMetrix markets a focused product portfolio consisting of the Quell hardware line and proprietary aftermarket consumables; according to the company, the majority of its revenue is generated from recurring aftermarket consumable sales, establishing a razor/blade model over its installed base of more than 5 million cumulative users worldwide.

NeuroMetrix sells directly to consumers through its own website with phone and email customer support, primarily targeting chronic pain patients, fibromyalgia patients, and users managing diabetic peripheral neuropathy. Since December 2024, NeuroMetrix has operated as a wholly-owned subsidiary of electroCore, Inc. (NASDAQ: ECOR), continuing to provide Quell products and services under its established brand while sharing electroCore's corporate office in Rockaway, New Jersey. The strategic rationale for the acquisition is to integrate NeuroMetrix's wearable neuromodulation platform into electroCore's non-invasive bioelectronic therapy portfolio, expanding combined reach into the broader chronic pain and neurological disorder markets.

Short descriptiontext

NeuroMetrix is a US medical device company that develops the FDA-authorized Quell wearable neuromodulation platform for chronic pain and fibromyalgia management. It serves over 5 million cumulative users globally via direct-to-consumer sales of devices and recurring proprietary consumables, and is now a wholly-owned subsidiary of electroCore, Inc.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockaway, United States
HQ citystring
Rockaway
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable neuromodulation devices, chronic pain management, fibromyalgia treatment devices, diabetic neuropathy diagnostics, non-invasive neurostimulation
Industry3 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYCRACAQAK
Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Neuromodulation Medical Devices
Social media profiles2 records
Revenue model2 records
1Quell Device Hardware Sales
TypeHardware Sales
Description

Sale of wearable neuromodulation devices (Quell, Quell Fibromyalgia) to patients and consumers for at-home chronic pain management.

neurometrix.com
2Proprietary Consumables (Aftermarket)
TypeSubscription Recurring
Description

Majority of revenue generated from aftermarket sales of proprietary consumables (electrode pads, accessories) required for ongoing use of the Quell devices.

neurometrix.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Quell
Description

Quell is NeuroMetrix's cloud-enabled wearable neuromodulation platform for chronic pain management and fibromyalgia treatment. It is the first and only FDA authorized medical device that helps reduce the symptoms of fibromyalgia.

neurometrix.com
Core offering1 text field

NeuroMetrix develops and globally commercializes non-invasive wearable medical devices for the diagnosis and treatment of pain and neurological disorders. Its flagship offering is the Quell wearable neuromodulation platform, including the Quell Fibromyalgia device — the first and only FDA-authorized medical device for reducing fibromyalgia symptoms — together with proprietary electrode consumables required for ongoing device use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 5 million people worldwide have benefited from NeuroMetrix healthcare products
Product overview1 text field

NeuroMetrix offers a focused product portfolio centered on its Quell® wearable neuromodulation platform. The core product is the Quell® Fibromyalgia device, an FDA-authorized wearable neuromodulator for chronic pain and fibromyalgia symptom management. The company also develops proprietary consumables that work with its devices, with consumable aftermarket sales representing the majority of revenue. In December 2024, NeuroMetrix became a wholly-owned subsidiary of electroCore, Inc., and continues to operate under its established Quell brand.

Product and service1 record
1Quell Fibromyalgia
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In December 2024 or May 2025 (sources conflict on exact date), electroCore acquired NeuroMetrix as a wholly-owned subsidiary to expand its neurotechnology offerings and integrate NeuroMetrix's cloud-enabled wearable neuromodulation platform. The acquisition enhanced electroCore's non-invasive bioelectronic therapy portfolio with NeuroMetrix's Quell system for chronic pain management and fibromyalgia treatment.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Parent company of NeuroMetrix; commercializes gammaCore, a non-invasive vagus nerve stimulation device for migraine and cluster headache. Directly comparable non-invasive bioelectronic therapy platform with overlapping payer, prescriber, and patient engagement models.

TypeDirect peer
Description

Developer of Cala Trio, a wearable TENS device for essential tremor and now chronic disease indications. Closest comparable wearable, non-invasive, prescription-or-DTC neurostimulation platform with a similar consumables-based recurring revenue model.

TypeDirect peer
Description

Pioneer in peripheral nerve stimulation (PNS) systems such as the Sprint PNS System for chronic and acute pain. Comparable neuromodulation platform targeting overlapping chronic pain and post-surgical pain indications, though delivered via minimally-invasive percutaneous leads.

TypeBroad incumbent
Description

Medical device company commercializing the Senza spinal cord stimulation (SCS) system for chronic pain, including 10 kHz HF therapy. Operates in the same neuromodulation category as NeuroMetrix, with a physician-implanted (rather than wearable) approach.

TypeBroad incumbent
Description

Global medical device leader with broad neuromodulation portfolio (Activa DBS, Intellis SCS, Vanta PCNS, InterStim sacral nerve stimulation). Competes for the same chronic pain, neurological disorder, and movement disorder patient populations as NeuroMetrix via implanted systems.

6Abbott
TypeBroad incumbent
Description

Diversified medical device company with the Proclaim XR family of SCS systems and dorsal root ganglion (DRG) stimulation for chronic pain. Comparable neuromodulation modality addressing the same chronic pain patient pool as Quell.

TypeBroad incumbent
Description

Operates a large neuromodulation franchise (Precision Spectra WaveWriter SCS, Vercise DBS, Axonics sacral neuromodulation, and recently acquired Neuromodulation Solutions). Competes across the neuromodulation spectrum that NeuroMetrix addresses for chronic pain.

TypeBroad incumbent
Description

Develops the Inspire hypoglossal nerve stimulation implant for obstructive sleep apnea. Comparable neurostimulation business model with a hardware-plus-accessory consumable structure and physician-channel reimbursement-driven demand.

TypeEmerging player
Description

Developer of wearable neurostimulation devices including DrugRelief for post-operative pain and anxiety relief. Closely comparable form factor (wearable, non-invasive electrical nerve stimulation) and similar indication overlap in chronic pain.

TypeEmerging player
Description

Digital musculoskeletal care platform combining virtual PT, wearable sensors (Enso), and AI-guided exercise programs for chronic back and joint pain. Competes with Quell for the same chronic pain patient population via a non-device, software-led alternative.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroMetrix

Wearable Neuromodulation Medical Devicesneurometrix.com

NeuroMetrix is a US medical device company that develops the FDA-authorized Quell wearable neuromodulation platform for chronic pain and fibromyalgia management. It serves over 5 million cumulative users globally via direct-to-consumer sales of devices and recurring proprietary consumables, and is now a wholly-owned subsidiary of electroCore, Inc.

What NeuroMetrix does

NeuroMetrix is a US-based medical device company founded in 1996 that develops and commercializes non-invasive wearable neuromodulation devices for chronic pain management and neurological disorders. The company pioneered the concept of automated nerve testing and introduced the Quell platform, billed as the first wearable nerve stimulator for managing chronic pain. Its flagship commercial product is the Quell Fibromyalgia device, an advanced wearable neuromodulator described as the first and only FDA-authorized medical device for reducing fibromyalgia symptoms.

The company's core technology is a cloud-enabled wearable neuromodulation platform that delivers non-invasive nerve stimulation to reduce chronic pain signals, paired with proprietary consumable electrode pads required for ongoing device use. NeuroMetrix markets a focused product portfolio consisting of the Quell hardware line and proprietary aftermarket consumables; according to the company, the majority of its revenue is generated from recurring aftermarket consumable sales, establishing a razor/blade model over its installed base of more than 5 million cumulative users worldwide.

NeuroMetrix sells directly to consumers through its own website with phone and email customer support, primarily targeting chronic pain patients, fibromyalgia patients, and users managing diabetic peripheral neuropathy. Since December 2024, NeuroMetrix has operated as a wholly-owned subsidiary of electroCore, Inc. (NASDAQ: ECOR), continuing to provide Quell products and services under its established brand while sharing electroCore's corporate office in Rockaway, New Jersey. The strategic rationale for the acquisition is to integrate NeuroMetrix's wearable neuromodulation platform into electroCore's non-invasive bioelectronic therapy portfolio, expanding combined reach into the broader chronic pain and neurological disorder markets.

NeuroMetrix firmographics

Firmographics
Name
NeuroMetrix
Legal name
NeuroMetrix, Inc.
Website
https://neurometrix.com
Company type
Private
Founded year
1996
Operating status
Acquired
Headcount range
11–50 employees
Short description
NeuroMetrix is a US medical device company that develops the FDA-authorized Quell wearable neuromodulation platform for chronic pain and fibromyalgia management. It serves over 5 million cumulative users globally via direct-to-consumer sales of devices and recurring proprietary consumables, and is now a wholly-owned subsidiary of electroCore, Inc.
Ownership category
akta.pro rank

NeuroMetrix industry classification

Industry
Product category
Wearable Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYCRACAQAK
Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Wearable neuromodulation devices
  • Chronic pain management
  • Fibromyalgia treatment devices
  • Diabetic neuropathy diagnostics
  • Non-invasive neurostimulation

Where NeuroMetrix is headquartered

Location

Headquarters

HQ city
Rockaway
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuroMetrix business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Quell Device Hardware Sales: Sale of wearable neuromodulation devices (Quell, Quell Fibromyalgia) to patients and consumers for at-home chronic pain management.
  2. Proprietary Consumables (Aftermarket): Majority of revenue generated from aftermarket sales of proprietary consumables (electrode pads, accessories) required for ongoing use of the Quell devices.

Distribution channels1 record

Marketing channels2 records

NeuroMetrix product offering

Product offering

Core offering

NeuroMetrix develops and globally commercializes non-invasive wearable medical devices for the diagnosis and treatment of pain and neurological disorders. Its flagship offering is the Quell wearable neuromodulation platform, including the Quell Fibromyalgia device — the first and only FDA-authorized medical device for reducing fibromyalgia symptoms — together with proprietary electrode consumables required for ongoing device use.

Product overview

NeuroMetrix offers a focused product portfolio centered on its Quell® wearable neuromodulation platform. The core product is the Quell® Fibromyalgia device, an FDA-authorized wearable neuromodulator for chronic pain and fibromyalgia symptom management. The company also develops proprietary consumables that work with its devices, with consumable aftermarket sales representing the majority of revenue. In December 2024, NeuroMetrix became a wholly-owned subsidiary of electroCore, Inc., and continues to operate under its established Quell brand.

Differentiator

Problem solved

Functional benefit

Brands

  • Quell: Quell is NeuroMetrix's cloud-enabled wearable neuromodulation platform for chronic pain management and fibromyalgia treatment. It is the first and only FDA authorized medical device that helps reduce the symptoms of fibromyalgia.

Products and services

  • Quell Fibromyalgia

Quantifiable outcome

  • Over 5 million people worldwide have benefited from NeuroMetrix healthcare products

Companies that use NeuroMetrix

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

NeuroMetrix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NeuroMetrix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • electroCore, Inc.coreStrategic or Co-development PartnerIn December 2024 or May 2025 (sources conflict on exact date), electroCore acquired NeuroMetrix as a wholly-owned subsidiary to expand its neurotechnology offerings and integrate NeuroMetrix's cloud-enabled wearable neuromodulation platform. The acquisition enhanced electroCore's non-invasive bioelectronic therapy portfolio with NeuroMetrix's Quell system for chronic pain management and fibromyalgia treatment.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

NeuroMetrix competitors and assessment

Company assessment

Broad incumbents

  • electroCore: Parent company of NeuroMetrix; commercializes gammaCore, a non-invasive vagus nerve stimulation device for migraine and cluster headache. Directly comparable non-invasive bioelectronic therapy platform with overlapping payer, prescriber, and patient engagement models.
  • Nevro: Medical device company commercializing the Senza spinal cord stimulation (SCS) system for chronic pain, including 10 kHz HF therapy. Operates in the same neuromodulation category as NeuroMetrix, with a physician-implanted (rather than wearable) approach.
  • Medtronic: Global medical device leader with broad neuromodulation portfolio (Activa DBS, Intellis SCS, Vanta PCNS, InterStim sacral nerve stimulation). Competes for the same chronic pain, neurological disorder, and movement disorder patient populations as NeuroMetrix via implanted systems.
  • Abbott: Diversified medical device company with the Proclaim XR family of SCS systems and dorsal root ganglion (DRG) stimulation for chronic pain. Comparable neuromodulation modality addressing the same chronic pain patient pool as Quell.
  • Boston Scientific: Operates a large neuromodulation franchise (Precision Spectra WaveWriter SCS, Vercise DBS, Axonics sacral neuromodulation, and recently acquired Neuromodulation Solutions). Competes across the neuromodulation spectrum that NeuroMetrix addresses for chronic pain.
  • Inspire Medical Systems: Develops the Inspire hypoglossal nerve stimulation implant for obstructive sleep apnea. Comparable neurostimulation business model with a hardware-plus-accessory consumable structure and physician-channel reimbursement-driven demand.

Direct peers

  • Cala Health: Developer of Cala Trio, a wearable TENS device for essential tremor and now chronic disease indications. Closest comparable wearable, non-invasive, prescription-or-DTC neurostimulation platform with a similar consumables-based recurring revenue model.
  • SPR Therapeutics: Pioneer in peripheral nerve stimulation (PNS) systems such as the Sprint PNS System for chronic and acute pain. Comparable neuromodulation platform targeting overlapping chronic pain and post-surgical pain indications, though delivered via minimally-invasive percutaneous leads.

Emerging players

  • DyAnsys: Developer of wearable neurostimulation devices including DrugRelief for post-operative pain and anxiety relief. Closely comparable form factor (wearable, non-invasive electrical nerve stimulation) and similar indication overlap in chronic pain.
  • Hinge Health: Digital musculoskeletal care platform combining virtual PT, wearable sensors (Enso), and AI-guided exercise programs for chronic back and joint pain. Competes with Quell for the same chronic pain patient population via a non-device, software-led alternative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

NeuroMetrix social profiles

Digital presence

NeuroMetrix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroMetrix leadership team

Management profile

Number of profiles

Profiles6 records

NeuroMetrix funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroMetrix M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroMetrix

What does NeuroMetrix do?

NeuroMetrix develops and globally commercializes non-invasive wearable medical devices for the diagnosis and treatment of pain and neurological disorders. Its flagship offering is the Quell wearable neuromodulation platform, including the Quell Fibromyalgia device — the first and only FDA-authorized medical device for reducing fibromyalgia symptoms — together with proprietary electrode consumables required for ongoing device use.

Is NeuroMetrix a public or private company?

NeuroMetrix is a private company. It is classified as corporate owned and is currently acquired.

When was NeuroMetrix founded?

NeuroMetrix was founded in 1996. It employs 11 to 50 people.

Where is NeuroMetrix based?

NeuroMetrix is headquartered in Rockaway, United States, in the North America region.

How does NeuroMetrix make money?

Two revenue lines are on record. Quell Device Hardware Sales are the primary driver. The others are proprietary Consumables (Aftermarket).

Who are NeuroMetrix's main competitors?

Broad incumbents on record are electroCore, Nevro, Medtronic, Abbott, Boston Scientific and Inspire Medical Systems. Direct peers are Cala Health and SPR Therapeutics. Emerging players are DyAnsys and Hinge Health.

Does NeuroMetrix have an API?

No public API is recorded for NeuroMetrix.

What industry is NeuroMetrix in?

NeuroMetrix's product category is Wearable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAnalysis of Key Market Segments Influencing the Neurotechnology MarketThe neurotechnology market is projected to reach $33.64 billion by 2030, growing at a compound annual growth rate of 14.1%, driven by advancements in brain-computer interfaces, AI-driven diagnostics, and non-invasive neurostimulation devices. In May 2025, US-based electroCore acquired NeuroMetrix for an undisclosed sum to expand its neurotechnology offerings and integrate NeuroMetrix's cloud-enabled wearable neuromodulation platform for chronic pain management. The market report also highlights Ethicon's 2024 launch of the ECHELON 3000 Stapler as an example of technological advances shaping surgical outcomes in the sector.openPR.comMarket Trend Analysis: The Impact of Recent Innovations on the Electrotherapy Systems MarketThe electrotherapy systems market is projected to grow to $7.98 billion by 2030 at a CAGR of 7.8%, driven by home-based rehabilitation demand, wearable device adoption, and aging populations. In May 2025, ElectroCore Inc. acquired NeuroMetrix Inc. to expand its non-invasive bioelectronic therapy portfolio by leveraging NeuroMetrix's Quell wearable neuromodulation system. The market is also seeing integration of wearable technologies with electrotherapy devices and increased demand for non-pharmacological pain management alternatives.openPR.comEmerging Sub-Segments Transforming the Bioelectronics Market LandscapeThe Business Research Company released a market report projecting the global bioelectronics market to reach $23.49 billion by 2030, growing at a compound annual growth rate of 11.1%, driven by AI-driven devices, IoT healthcare integration, and remote patient monitoring solutions. In May 2025, ElectroCore Inc. acquired NeuroMetrix, Inc., making it a wholly owned subsidiary to enhance its bioelectronic therapy offerings with NeuroMetrix's Quell wearable neuromodulation platform for chronic pain and fibromyalgia treatment. In July 2025, Fasikl Inc. received FDA 510(k) clearance and launched the Felix NeuroAI wristband, an AI-powered device for essential tremor management that delivers personalized neuromodulation therapy.FieldtexcasesClinical-Grade vs. Consumer Wearables: What Sets Them Apart?This article compares consumer-grade wearables (such as Fitbit and Apple Watch) with clinical-grade medical devices, explaining how FDA-approved clinical wearables offer superior accuracy, real-time monitoring, and treatment capabilities for chronic disease management. It profiles four FDA-approved clinical wearables—Biotricity Bioflux, Medtronic MiniMed 770G, NeuroMetrix Quell, and Bloomlife—and notes the growing market for medical-grade wearables driven by chronic disease rates and remote monitoring demand. The article serves as promotional content for Fieldtex Cases, a manufacturer of sewn components for medical wearable devices.ETF Daily NewsNeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.comStockNews.com analysts issued a sell rating on NeuroMetrix on Wednesday, with the stock opening at $4.37. Renaissance Technologies acquired a new stake of 11,560 shares, valued at about $46,000, and institutional investors hold 19.40% of the company.ETF Daily NewsNeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.comStockNews.com analysts initiated coverage on NeuroMetrix with a sell rating on Tuesday. The stock opened at $4.36, and GTS Securities bought a new stake of 22,759 shares, valued at about $90,000. Institutional investors hold 19.40% of the company.ETF Daily NewsStockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)StockNews.com initiated coverage on NeuroMetrix with a sell rating. Renaissance Technologies bought a new stake of 11,560 shares, valued at about $46,000, in Q4. The company's stock opened at $4.37 with a market cap of $8.93 million.ETF Daily NewsNeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.comStockNews.com analysts issued a sell rating on NeuroMetrix on Friday. The company reported a quarterly loss of $0.75 per share on revenue of $0.59 million, with a negative net margin of 203.71%. The stock opened at $4.21, trading above its 50-day moving average.ETF Daily NewsNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on NeuroMetrix with a sell rating on Wednesday. The stock opened at $3.98, and the company reported a Q3 loss of $0.75 per share on revenue of $0.59 million. The firm has a market cap of $8.13 million and a beta of 2.20.ETF Daily NewsNeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.comAnalysts at StockNews.com assumed coverage on NeuroMetrix, issuing a sell rating on Tuesday. The company reported a quarterly loss of $0.75 per share on revenue of $0.59 million, with a market cap of $8.11 million and a beta of 2.20.